Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease
Main finding · Drug retention rate, all tsDMARDsResult — go to the resultAdjusted hazard ratio 1.14 95% CI 0.81–1.62Authors' conclusion
tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD
Study context
- Population
- Patients with RA prescribed their first tsDMARDs at two hospitals, 2013–2022, categorised by kidney function
- Participants
- 216 patients
- Exposure
- First-line tsDMARDs by kidney function category
- Outcome
- Drug retention rate
- Follow-up
- 24 months
Methodological detailstwo hospitals
- Two hospitals
Main finding
Drug retention rate, all tsDMARDs
Adjusted hazard ratio
1.14
95% CI 0.81–1.62
P = 0.45
By group
Lower kidney function
aHR 1.14 (95% CI 0.81–1.62); P = 0.45
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
DAS28-CRP and prednisolone dose over 6 months after initiation
- Decreased DAS28-CRP
- P < 0.01
- Reduced prednisolone dosage
- P < 0.01
Safety
Herpes zoster and deep vein thrombosis (DVT)
- Incidence higher in estimated glomerular filtration rate (eGFR) <30 group, but not statistically significant
Original publication
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease. Rheumatology (Oxford). Published 25 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →